Japan Regulatory Timeline 2026-2027 for Medical Devices

1. Key takeaways

Japanese medical device regulation has three fixed milestones over the coming eighteen months: staged enforcement from November 20, 2025, principal enforcement on May 1, 2026 (conditional approval and the foreign known-case reporting adjustment), and full enforcement of governance and supply responsibility by May 2027. Measured from this verification date (October 29, 2026), the first two milestones are already in force, and the third is the current remediation window. GRZAN sets out 6 response actions. The milestone structure matters as much as the content of the changes: knowing which obligation matures on which date converts a single large amendment into a sequence of manageable work packages.

• Milestone one: staged enforcement begins November 20, 2025.
• Milestone two: May 1, 2026 brings conditional approval and the foreign known-case reporting change.
• Milestone three: governance and supply responsibility are fully enforced by May 2027.
• Six response actions cover pathways, vigilance, governance, D-MAH structure, milestone reviews and verification dating. The milestone structure matters as much as the content of the changes: knowing which obligation matures on which date converts a single large amendment into a sequence of manageable work packages.

2. Legal basis

The milestones rest on the amendment act and the instruments listed below, reproduced in the same terms as the source guidance. Each element should be re-confirmed against the current text on e-Gov before it is cited in external documents. Mapping each milestone to its instrument is what allows the compliance calendar to be built on legal citations rather than on assumptions.

1. Act Partially Amending the Acts Related to Assurance of Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc., Act No. 37 of 2025 (Reiwa 7), promulgated May 21, 2025, enforced in stages from November 20, 2025.
2. PMD Act Article 23-2-6-2 (conditional approval): enforced May 1, 2026.
3. Supporting ordinance: MHLW Ordinance No. 117 of 2025 (Reiwa 7); the amendment of the Implementing Rules was promulgated November 28, 2025 (for the provisions enforced from May 1, 2026).
4. MHLW notification Iyaku Kishinhatsu No. 0331-23 (March 31, 2026): handling of conditional approval, applicable from May 1, 2026.
5. The partial-revision notification on the handling of use-results evaluation (original notification Yakushoku Kisanhatsu No. 1121-44, November 21, 2014): exemption from the 30-day report for foreign known death and serious cases, applicable from May 1, 2026.
6. Governance and supply responsibility provisions: full enforcement within two years of promulgation (by May 2027).
7. Current legal framework: Act No. 145 of 1960.

3. Expert insights

Insight 1: the three milestones correspond to three different corporate responses. Enforcement from November 20, 2025 marks the start of the regime taking effect, and companies should complete a provision-by-provision comparison so that every internal procedure references the current text; the May 1, 2026 milestone delivers a pathway addition (conditional approval) and an obligation adjustment (the foreign known-case reporting exemption), and companies should complete a pathway reassessment and a workflow update; the May 2027 milestone is the remediation deadline, by which companies should close the governance and supply responsibility gaps. Sequencing the response in this way keeps each work package small enough to finish before its date, and prevents the governance workload from colliding with the pathway work.

Insight 2: a pathway addition and a reporting relief took effect the same day, in opposite directions. Two changes effective on the same day — one widening the boundary of what can be approved, one lightening the reporting burden — reflect the dual objectives within the same amendment: accelerating innovative access while raising the allocation efficiency of vigilance resources. For planning purposes the two should be owned separately: the pathway addition belongs to regulatory strategy, while the reporting relief belongs to the vigilance function.

Insight 3: roughly half a year remains in the current window. Counted from October 29, 2026, about six months remain until full enforcement in May 2027. For Chinese manufacturers that rely on an external license holder, this window determines whether the architecture is adjusted now or remediation is forced at the deadline. The remaining time is best spent on structural decisions — D-MAH selection, supply architecture and governance appointments — since procedural updates can be completed close to the deadline but structural ones cannot.

4. Practical recommendations

• Reassess the pathway portfolio for innovative devices. Evaluate conditional approval, pioneering designation and priority review side by side, and start the PMDA pre-development consultation, since consultation outcomes feed directly into the pathway decision.
• Update the vigilance workflow triage table. Remove the 30-day branch for foreign known death and serious cases, and retain the domestic and unknown branches.
• Close the governance and supply responsibility gaps. Implement the responsible officer, the quality assurance officer and the supply-system management officer one by one.
• Reassess the D-MAH architecture. Decide between appointing an external holder and building an in-house entity before May 2027.
• Institute a milestone re-verification mechanism. Each of the three milestones triggers one full re-verification of the compliance documentation, so that no obligation is managed against a text that has since moved.
• Write the verification date into all external documents. State the currency of regulatory conclusions through the verification date visible in the body text.

5. Verification checklist

• □ Has a compliance calendar been built on the three milestones (2025-11-20 / 2026-05-01 / 2027-05)?
• □ Has the pathway portfolio for innovative devices been reassessed, and the PMDA pre-development consultation started?
• □ Has the vigilance triage table been updated for the May 1, 2026 changes?
• □ Do the three governance and supply responsibility gaps each have remediation items and responsible persons?
• □ Is the D-MAH architecture decision scheduled for completion before May 2027?
• □ Is the verification date in external documents the latest re-verification date?

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, in-country representative and local testing support for the Japanese market. Our team manages adverse event reporting and recall coordination with PMDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com